Recent work has revealed that the NASH liver accumulates a higher number of activated PD-1-expressing CD8 T cells that further expand following anti-PD1 treatment but fail to prevent HCC (48). The gene discussed is CD8A; the disease is metabolic dysfunction-associated steatohepatitis.